Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)
Mizuho Securities, through analyst Uy Ear, reaffirmed a Buy rating for Arcutis Biotherapeutics with a price target of $37.00. The analyst covers the Healthcare sector and has an average return of -0.3% with a 38.24% success rate. The consensus among analysts is a Strong Buy rating with a $29.50 average price target for Arcutis Biotherapeutics.
In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics, with a price target of $37.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ear covers the Healthcare sector, focusing on stocks such as Tectonic Therapeutic, Arcutis Biotherapeutics, and Alkermes. According to TipRanks, Ear has an average return of -0.3% and a 38.24% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcutis Biotherapeutics with a $29.50 average price target.
